Atazanavir is metabolized in the liver with the participation of the cytochrome P450 system; it is also an inhibitor of the isoenzyme CYP3A4, included in this system.
The combined use of the drug Reatas® and other drugs with the same metabolic pathways, (slow calcium channel blockers, some 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HMG-CoA reductase), immunosuppressants, phosphodiesterase inhibitors) can lead to an increase in the concentration of one of them in the plasma, which may lead to an increase in the severity or prolongation of its therapeutic and side effects.
The combined use of the drug Reatase® and isozyme inducing drugs CYP3A4 (rifampicin), can lead to a significant drop in the concentration of atazanavir in plasma and a decrease in its therapeutic activity as a result. The combined use of the drug Reatase® and preparations inhibiting the isoenzyme CYP3A4, can lead to an increase in the concentration of atazanavir in plasma.
Extent isoenzyme CYP3A4 - mediated interactions of atazanavir with other drugs (changes in the effect of atazanavir or a change in the effect of another drug) may change with the use of the drug Reataz ® with ritonavir, a potent inhibitor of the isoenzyme CYP3A4.
For completeness of information on the interactions of drugs with ritonavir, you should read the instructions for the use of ritonavir.
Drugs that should not be taken with Reatase®:
Quinidine: Use with the combination of Reatase ® / ritonavir is contraindicated in connection with the risk of serious and life-threatening arrhythmias.
Rifampicin: with the simultaneous use of atazanavir with rifampicin, the concentration of atazanavir in the blood plasma is significantly reduced, which leads to a decrease in therapeutic effectiveness and the development of resistance to the preparation of Reataz®.
The simultaneous use of atazanavir and rifampicin is contraindicated.
Irinotecan: Atazanavir inhibits UDP-glucuronosyltransferase (CGT) and can affect the metabolism of irinotecan, causing an increase in its toxicity, so the combined use of atazanavir with irinotecan is contraindicated.
Bepridil: due to the high risk of developing life-threatening side effects, joint application with the drug Reataz® is contraindicated.
Derivatives of ergotamine (dihydroergotamine, ergotamine, ergometrine, methylergomethrin): due to the high risk of developing life-threatening side effects, joint application with the drug Reataz® is contraindicated. Manifestations of acute toxicity of ergotamine derivatives: peripheral vasospasm, ischemia of extremities and other zones.
Cisapride: in connection with the high risk of development of life-threatening side effects (arrhythmia), joint application with the preparation of Reataz® is contraindicated.
Lovastatin, simvastatin: increased risk of myopathy, including rhabdomyolysis.
Inhaled beta2-adrenomimetics (salmeterol): increased risk of developing side effects from the cardiovascular system inherent in salmeterol, including the lengthening of the interval Q-T, palpitation, sinus tachycardia. The combined use of salmeterol and Reatase® is not recommended.
Pimozide: in connection with the high risk of development of life-threatening side effects (arrhythmia), joint application with the preparation of Reataz® is contraindicated.
Indinavir: combined use with the drug Reatase ® is not recommended, since both drugs can cause hyperbilirubinemia.
Midazolam, triazolam: joint use with the drug Reataz ® is contraindicated in connection with the possibility of increasing the concentration of midazolam / triazolam and a high risk of prolonging sedation and respiratory depression.
Warfarin: when used together with the drug Reatase ® increases the risk of developing severe, life-threatening bleeding, so this combination is not recommended.
Preparations of St. John's wort perfumed (Hypericum perforatum): combination with with the drug Reatas ® is contraindicated, since the concentration of atazanavir in plasma may decrease, leading to a loss of therapeutic effect and the development of resistance.
Astemizole: when combined with a combination of the drug Reatase ® / ritonavir, the risk of developing severe, life-threatening side effects increases, so this combination is not recommended.
Terfenadine: when combined with a combination of the drug Reatase ® / ritonavir, the risk of developing severe, life-threatening side effects increases, so this combination is not recommended.
Alfuzosin: in view of the potential increase in the concentration of alfuzosin, which may lead to the development of hypotension, a combined use with the combination of the drug Reatase® / ritonavir is not recommended.
For the drugs listed below, you may need to change the dosage regimen in connection with the expected interactions:
Antiretroviral drugs for HIV treatment
Nucleoside reverse transcriptase inhibitors:
Didanosine: the use of enteranasol-coated didanosine capsules together with the preparation of Reatase® or with preparations of Reatas® and / or ritonavir and food reduces the bioavailability of didanosine. Didanosine should be taken 2 hours after taking the drug Reatas ®.
Nucleotide reverse transcriptase inhibitors:
Tenofovir: Tenofovir reduces the activity of atazanavir with simultaneous application, atazanavir increases the concentration of tenofovir in blood plasma. High concentrations of tenofovir may exacerbate the side effects associated with taking tenofovir, including effects on kidney function, so monitor the side effects of tenofovir in patients.
Non-nucleoside reverse transcriptase inhibitors:
Efavirenz: combination therapy with Reatas® and efavirenz leads to a decrease in the effect of the drug, Reatas®, and should therefore be avoided. If the use of this combination is absolutely necessary, it is permitted to use it only in patients who have not previously received antiretroviral therapy. In this case, Reamaz® 400 mg and ritonavir 100 mg are given as a single dose during meals, and efavirenz - on an empty stomach, before bedtime.
Nevirapine: nevirapine, being an inducer of isoenzyme CYP3A4, reduces the effect of atazanavir. In addition, due to an increase in the concentration of nevirapine, its toxicity increases, so this combination is not recommended.
Protease inhibitors:
Boceprevir: when combined with Reatas® 300 mg / ritonavir 100 mg once daily with bocetrevir in a dose 800 mg three times a day, the concentration of atazanavir in the blood decreases, while the concentration of boceprevir does not change significantly.
Saquinavir (soft gelatin capsules): the effect of saquinavir increases when taken together with the preparation of Reataz®. There are no data allowing to give appropriate recommendations for dosing this combination.
Ritonavir: when combined with the preparation of Reatas ®, the concentration of atazanavir increases.
Other HIV protease inhibitors: simultaneous application of combination Reatase® / ritonavir with other HIV protease inhibitors is not recommended.
Other drugs
Antacids and buffering preparations: when combined with antacids and buffer preparations, the concentration of atazanavir in blood plasma decreases. Reatase® should be used 2 hours before or 1 hour after taking such drugs. Antiarrhythmic drugs:
Amiodarone, lidocaine (with parenteral administration), quinidine: while simultaneous application with the preparation of Reatas ®, it is possible to increase their concentrations. Admission in such combinations requires increased caution, it is recommended to monitor the concentration of these drugs in the plasma. The combination of Reatase® / ritonavir is contraindicated for joint use with quinidine because of the possibility of serious or life-threatening reactions (arrhythmia).
Beta-blockers:
Atenolol: with the simultaneous use of the drug Reatase ® with beta-blockers clinically significant pharmacokinetic interactions are not expected, therefore correction of the dosing regimen is not required.
Blocks of "slow" calcium channels:
Diltiazem: joint application with the preparation of Reatas ® leads to an increase in the action of diltiazem and its metabolite - deacetyl-dithiasem. It is recommended to reduce the dose of diltiazem by 50% and ECG monitoring.
Other blockers of "slow" calcium channels, such as felodipine, nifedipine, nicardipine and verapamil: caution should be exercised when combined, titration of the dose of "slow" calcium channel blockers, ECG monitoring is necessary.
Endothelin receptor antagonists (bosentan): bosentan is metabolized by isoenzyme CYP3A4, being its inductor. The concentration of atazanavir in plasma may decrease with simultaneous use of the preparation of Reatas ® with bosentan, but without ritonavir. In this regard, the combination of Reatas® / bosentan can only be used with ritonavir. The following are the dosing regimes:
- The appointment of bosentan to patients taking Reatase® / ritonavir for at least 10 days: bosentan in a dose of 62.5 mg once a day or every other day (depending on individual tolerability).
- Assign a combination of Reatase® / ritonavir to patients taking bosentan: stop taking bosentan at least 36 hours before taking the combination of Reatas® / ritonavir.Not earlier than 10 days after starting the combination of Reatas® / ritonavir, resumption of bosentan at a dose of 62.5 mg once a day or every other day (depending on individual tolerability).
Inhibitors of HMG-CoA reductase:
Atorvastatin: when combined with the preparation of Reatas ®, the effect of atorvastatin may be enhanced. The risk of myopathy, including rhabdomyolysis, may increase. Care must be taken. The lowest effective doses of atorvastatin should be used in combination with the drug Reatase® or Reatase® / ritonavir.
Rosuvastatin: The dose of rosuvastatin when combined with atazanavir should not exceed 10 mg / day. With simultaneous use of rosuvastatin and atazanavir, the risk of myopathy increases, including rhabdomyolysis.
Pravastatii, fluvastatin: the potential of interactions in combination with the drug Reatase® or Reatase® / ritonavir is unknown.
Proton Pump Inhibitors: During treatment with the preparation of Reatas ®, proton pump inhibitors are prescribed only if their use is highly indicated.
With the simultaneous use of the drug Reatas ® 400 mg or a combination of Reatas ® 300 mg / ritonavir 100 mg with omeprazole 40 mg (all preparations once a day) concentrations of atazanavir in blood plasma were significantly reduced,which can lead to a decrease in the therapeutic activity of the drug and to the development of resistance.
Patients with HIV in the absence of a possible or identified decrease in sensitivity to atazanavir are recommended to use a combination of Reatas® 400 mg / ritonavir 100 mg with omeprazole at a maximum dose of 20 mg once daily (or another drug from the proton pump inhibitor group at the equivalent dose).
It is not recommended to apply omeprazole at a dose of more than 20 mg per day (or another drug from the proton pump inhibitor group at the equivalent dose).
Blockers of H2-histamine receptors: the concentration of atazanavir in blood plasma was significantly reduced by the simultaneous use of the preparation of Reatas ® 400 mg once a day with famotidine 40 mg twice a day, which may lead to a decrease in the therapeutic activity of the drug or to the development of resistance.
In the treatment of patients who had not previously received therapy, Reatase® 400 mg can be applied once a day with food 2 hours before and no later than 10 hours after the use of H2-histamine receptor blockers. However, a single dose of H2-histamine receptor blockers should not exceed the dose corresponding to a dose of famotidine 20 mg, and the total daily dose should not exceed the dose corresponding to 40 mg of famotidine.
Alternatively, Reatas® 300 mg with ritonavir 100 mg can be applied once a day during meals, 2 hours before and not less than 10 hours after the use of H2-histamine receptor blockers in a single dose comparable to 40 mg famotidine.
In the treatment of patients who had previously received therapy, the daily dose of H2-histamine receptor blockers should not exceed the dose corresponding to 40 mg of famotidine. In such patients, Reatase® 300 mg / ritonavir 100 mg should be taken once a day with food 2 hours before and no later than 12 hours after the use of H2-histamine receptor blockers (once a day) at a dose corresponding to 40 mg famotidine . Alternatively, Reatas® 300 mg / ritonavir 100 mg can be applied once a day with meals simultaneously with H2-histamine receptor blockers, 2 hours before and not less than 10 hours after the use of H2-histamine receptor blockers in a dose not exceeding dose, which corresponds to 20 mg of famotidine. This dose can be taken once or twice a day. When such patients are prescribed a combination of Reatase® / ritonavir and tenofovir with the H2-histamine receptor blocker, the following dosing regimen should be used: Reatas® 400 mg and ritonavir 100 mg once daily.
Immunosuppressants (ciclosporin, tacrolimus, sirolimus): in joint application of cyclosporine, tacrolimus, sirolimus and the preparation of Reataz® is possible increasing the concentration of immunosuppressants in the blood, therefore, monitoring of their concentrations is recommended.
Antidepressants:
Tricyclic antidepressants: when combined with the use of the drug Reatase with tricyclic antidepressants, serious and / or life-threatening adverse reactions associated with antidepressants may occur. It is recommended to monitor the concentrations of these drugs when used together with the drug Reatase®.
Trazodone: with the combined use of trazodone with the drug Reataz® or with the combination of Reatas® / ritonavir, an increase in trazodone concentration in the blood plasma is possible. With the combined use of trazodone and ritonavir, nausea, dizziness, low blood pressure, and a brief loss of consciousness were reported. In the joint use of trazodone with inhibitors of isoenzyme CYP3A4, such as Reatase®, smaller doses of trazodone should be used.
Benzodiazepines: Midazolam is metabolized by isoenzyme CYP3A4. Despite the fact that no studies have been conducted, with the combined use of the drug Reatas ® and midazolam, one can expect a significant increase in the concentration of the latter. In this case, an increase in the concentration of midazolam with oral administration will be significantly higher than with parenteral administration. The use of the drug Reataz® together with midazolam for oral administration is contraindicated. Data on simultaneous use of the drug Reataz ® with midazolam in the form of injections are absent; on the basis of data on the simultaneous use of other HIV protease inhibitors with midazolam, a possible increase in the concentration of midazolam in the plasma is 3-4 times. With the combined use of the drug Reatase ® with injection midazolam should be careful, control the respiratory function and the duration of sedation. In some cases, a correction of the dosing regimen is necessary.
Antiepileptic drugs:
Carbamazepine: with the simultaneous administration of carbamazepine and the preparation of Reatas® without ritonavir, the concentration of atazanavir in blood plasma may decrease.In this regard, the simultaneous administration of carbamazepine and the preparation of Reataz® without ritonavir is not recommended. Because the ritonavir can increase the concentration of carbamazepine in blood plasma, in patients taking carbamazepine and those beginning treatment with the drug Reatase® and ritonavir, a dose reduction of carbamazepine may be required.
Phenytoin, phenobarbital: with the simultaneous administration of phenytoin or phenobarbital and the preparation of Reatas® without ritonavir, the concentration of atazanavir in the blood plasma may decrease. In this regard, the simultaneous administration of phenytoin or phenobarbital and the preparation of Reataz® without ritonavir is not recommended. Because the ritonavir can reduce the concentration of phenytoin and phenobarbital in the blood plasma, in patients taking phenytoin or phenobarbital in conjunction with the drug Reatase ® and ritonavir, a dose adjustment of phenytoin or phenobarbital may be required.
Lamotrigine: with the simultaneous use of lamotrigine and the preparation of Reatas ® with ritonavir, the concentration of lamotrigine in blood plasma may decrease. In this regard, you may need to adjust the dose of lamotrigine.With the simultaneous use of lamotrigine and the preparation of Reatas® without ritonavir, a decrease in the concentration of lamotrigine in the blood plasma was not observed, therefore, lamotrigine dose adjustment is not required.
Macrolide antibiotics:
Clarithromycin: with the combined use of clarithromycin with the preparation of Peytaz®, the concentration of clarithromycin increases, which can cause lengthening QT-interval, so the dose of antibiotic should be reduced by 50%.
Oral contraceptives:
Ethinylestradiol and norethisterone or norgestimate: when combined with the preparation of Reatas ®, concentrations of ethinylestradiol and norethisterone increase. The combined use of the combination of Reatas® / ritonavir with ethinyl estradiol and norgestimate reduces the average concentration of ethinylestradiol and increases the average concentration of 17-deacetylnorgestimate, the active metabolite of norgestimate.
In the case of combined use of oral contraceptives and a combination of Reatas ® / ritonavir, contraceptives with an ethinyl estradiol content of at least 30 μg are recommended. If Reatase® is used with contraceptives without ritonavir, the content of ethinylestradiol in oral contraceptives should not exceed 30 μg.With the combined use of the drug Reatase ® and oral contraceptives should be careful, because the effect of increasing the concentration of progestogens is unknown; the risk of developing acne, dyslipidemia and insulin resistance may increase. With increasing concentration norethisterone, it is possible to reduce the concentration of HDL or increase insulin resistance, especially in women with concomitant diabetes mellitus.
It is recommended to use the lowest effective doses of each component of oral contraceptive, it is also advisable to use other reliable methods of contraception. The combined use of the drug Reatase® or a combination of Reatas® / ritonavir with other forms of hormonal contraceptives (contraceptive patches, contraceptive vaginal rings, injectable contraceptives) or with oral contraceptives containing progestogens other than norethisterone or norgestimate, as well as with preparations containing less than 25 μg ethinylestradiol has not been studied, therefore these contraceptive methods should not be used in conjunction with the preparation of Reatas®.
Preparations for the treatment of gout (colchicine): colchicine is a substrate of isoenzyme CYP3A4, its effect can be enhanced when it is applied simultaneously with the preparation of Reatas ®.
Recommended doses of colchicine when used concomitantly with the preparation of Reataz® are given below.
Acute attack of gout: 0.6 mg - the first dose, then 0.3 mg an hour after the first dose. Repeated application of this scheme is possible not earlier than in 3 days.
Prevention of acute gout attacks:
- if the usual dosing regimen was 0.6 mg 2 times a day, the dose should be reduced to 0.3 mg 2 times a day;
- if the usual dosing regimen was 0.6 mg once a day, the dose should be reduced to 0.3 mg every other day.
Family Mediterranean fever: the maximum daily dose of colchicine is 0.6 mg. This dose can be divided into 2 doses - 0.3 mg 2 times a day.
Antimycobacterial drugs:
Rifabutin: The activity of rifabutin when used together with the preparation of Reatas® is increased. With the simultaneous administration of these drugs, a dose reduction of rifabutin to 75% of the usual dose is recommended: 150 mg every other day or three times a week. Careful monitoring of adverse reactions in patients taking rifabutin and Reatase® or a combination of Reatase® / ritonavir; further correction of the dose of rifabutin may be required.
Inhibitors of phosphodiesterase-5 (PDE-5):
Application for erectile dysfunction
Sildenafil, tadalafil, vardenafil: with the combined use of HIV protease inhibitors with phosphodiesterase-5 inhibitors, a significant increase in the concentration of phosphodiesterase-5 inhibitors and an increase in their side effects are possible. Dose reduction is recommended: sildenafil - 25 mg not more often than every 48 hours when applied with or without ritonavir; tadalafil - 10 mg not more often than every 72 hours when applied with or without ritonavir; vardenafil - 2.5 mg not more often than every 72 hours when used with ritonavir and 2.5 mg not more often than every 24 hours when used without ritonavir; monitoring of adverse reactions is necessary.
Application for pulmonary hypertension
Sildenafil: The use of together with the drug Reatase ® with pulmonary hypertension is contraindicated.
Tadalafil:
- for patients taking the drug Reataz® for at least seven days: tadalafil prescribe a dose of 20 mg 1 time per day. The dose can be increased to 40 mg once a day (depending on individual tolerability);
- for patients taking tadalafil: stop taking tadalafil at least 24 hours before taking Reataz®. Not earlier than seven days after the start of taking the drug Reataz ®, resume taking tadalafil 20 mg once a day. The dose can be increased to 40 mg once a day (depending on individual tolerability);
Antifungal preparations:
Ketoconazole, itraconazole: Only joint use of ketoconazole with the preparation of Reataz® without ritonavir was studied; Atazanavir concentrations increase slightly with this combination.
Ketoconazole and itraconazole can increase concentrations of atazanavir and ritonavir in blood plasma. Caution should be exercised when using ketoconazole and itraconazole in daily doses above 200 mg in combination with a combination of Reatase® / ritonavir.
Voriconazole: combined use of voriconazole (200 mg twice daily) with a combination of Reatas® / ritonavir in patients with at least one functional isoenzyme allele CYP2C19 led to a decrease in the concentrations of voriconazole and atazanavir in blood plasma. The combined use of voriconazole (200 mg twice daily) with the combination of Reatas® / ritonavir in patients without a functional isoenzyme allele CYP2C19 led to an increase in the concentrations of voriconazole and a decrease in the concentration of atazanavir in the blood plasma.
The combined use of voriconazole and the combination of Reatase® / ritonavir is recommended only when the potential benefit of voriconazole is greater than the risk. When using this combination therapy, careful monitoring of the side effects of voriconazole, as well as the efficacy of voriconazole and atazanavir, should be carried out, which may decrease.
Anticoagulants:
Warfarin: Because of the increased activity of warfarin, simultaneous use with the drug Reatase® can cause severe and / or life-threatening bleeding. It is recommended to monitor the international normalized attitude (INR).
Inhalation / nasal glucocorticosteroids (interaction with ritonavir): when ritonavir was used together with fluticasone propionate by healthy volunteers, the concentration of cortisol was significantly reduced due to a significant increase in the concentration of fluticasone in plasma. The combined use of a combination of Reatase® / ritonavir with fluticasone propionate may lead to a similar effect.
With the joint use of ritonavir and inhalation (or intranasal) preparations of fluticasone propionate, the development of systemic side effects of glucocorticosteroids (Isenko-Cushing syndrome, suppression of the adrenal cortex) was noted. Similar effects are possible and when combined with other glucocorticosteroids metabolized by isoenzyme CYP3A4, for example, budesonide. In this regard, the use of a combination of Reatas® / ritonavir together with fluticasone propionate or other glucocorticosteroids metabolized by isoenzyme CYP3A4, is justified only if the potential benefit of therapy exceeds the risk of systemic effects of glucocorticosteroids. When combined with Reatas® (without ritonavir) and fluticasone propionate, the concentration of the drug in the plasma may increase. Care should be taken and, if possible, drugs that do not contain fluticasone propionate, especially with prolonged use.
Substrates of other cytochrome P450 isoenzymes (CYP):
Clinically significant interactions between atazanavir and isozyme substrates CYP2C19, CYP2C9, CYP2D6, CYP2B6, CYP2A6, CYP1A2 or CYP2E1 not expected. Atazanavir - weak isoenzyme inhibitor CYP2C8. Caution should be exercised when using the drug Reatase ® (without ritonavir) and preparations heavily dependent on isoenzyme CYP2C8 and having a narrow therapeutic profile (for example, paclitaxel, repaglinide). When using a combination of Reatase® / ritonavir together with isoenzyme substrates CYP2C8 clinically significant interactions are not expected.
Narcotic analgesics:
Buprenorphine: in connection with the inhibition of isoenzymes CYP3A4 and UGT1A1 when combined with Reatas® or a combination of Reatase® / ritonavir and buprenorphine, concentrations of buprenorphine and norbuprenorphine were increased. With the use of the combination of Reatase ® / ritonavir and buprenorphine, no significant change in the concentration of atazanavir in plasma was detected; the use of the same combination, but without ritonavir, can lead to a significant decrease in the concentration of atazanavir in plasma. When the combination of Reatas® / ritonavir and buprenorphine is used concomitantly, careful monitoring of the patient's condition is necessary (evaluation of sedation and cognitive functions).You may need to reduce the dose of buprenorphine.
For the drugs listed below, clinically important interactions are not expected, so there is no need to adjust the dose of drugs:
Lamivudine + zidovudine: when combined with a 400 mg dose of Reatase ®, no significant changes in the concentrations of lamivudine and zidovudine were observed. Also, there is no significant change in the pharmacokinetic parameters of nucleoside reverse transcriptase inhibitors under the influence of ritonavir. Given these data, no significant change in the concentrations of lamivudine and zidovudine is expected when combined with the combination of the drug Reatase® / ritonavir.
Abacavir
When combined with a combination of the drug Reatase ® / ritonavir, no significant change in the concentration of abacavir is expected.
Raltegravir
When combined with a combination of the preparation of Reatas® / ritonavir, an increase in the area under the curve (AUCs) for raltegravir by 41%, the maximum equilibrium concentration of raltegravir (Cma) by 24%, the equilibrium concentration of raltegravir after 12 hours (C 12h) by 77%. Correction of doses of raltegravir is not required.
Fluconazole
When combined with the combination of the drug Reatas ® / ritonavir, no significant changes in the concentrations of atazanavir and fluconazole were observed. Correction of the dose is not required.